Physician profile
Terry Saunders
NPI 1740301191
$4,451.32
in general payments reported to CMS, 2019-2025
13 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,149 · 2023: $26.28 · 2024: $856 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,626.37 | 2021-2025 | Epclusa, Yeztugo, Biktarvy |
| Abbvie INC. | $655.24 | 2024-2025 | |
| Madrigal Pharmaceuticals | $616.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Viiv Healthcare Company | $580.80 | 2021-2025 | Apretude, Rukobia |
| Merck Sharp & Dohme LLC | $234.48 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Indivior INC. | $175.85 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $147.59 | 2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $119.47 | 2025 | Wegovy |
| Janssen Biotech, INC. | $118.54 | 2021 | |
| Janssen Products, LP | $99.99 | 2021 | |
| Alkermes, INC. | $29.16 | 2025 | Vivitrol |
| Organon LLC | $26.28 | 2023 | Nexplanon |
| Emd Serono, INC. | $20.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.